Novartis, SciNeuro Sign USD 1.7 Billion Licensing Deal to Develop Alzheimer's Therapies
Novartis has entered into an exclusive global licensing and collaboration agreement with SciNeuro Pharmaceuticals to develop and commercialize novel therapies for Alzheimer’s disease, in a deal valued at up to USD 1.7 billion.
SciNeuro | 13/01/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy